Latest News
Retatrutide Black Market: Lilly Sues Six US Sellers
Eli Lilly has filed six lawsuits against United States companies. It accuses them of selling illegal versions of its experimental obesity drug, which remains in Phase 3 trials. The retatrutide black market runs through peptide websites, medical spas and wellness...
Latest News
From Reactive Reviews to Predictive Regulatory Intelligence
Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....
The Patient as Healthcare’s Systems Integrator
Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...
Why AI in Life Sciences Lives or Dies on its Data Foundations
AI has moved quickly in the life sciences making exciting breakthroughs and reframing how we think about healthcare. But beneath these breakthroughs, work is happening in places that rarely make headlines, data catalogues, validation plans, audit trails, integration...
Healthcare’s Claim-Denial Crisis Is an Administrative Epidemic
Healthcare has a second epidemic running alongside every clinical one, and it doesn't show up on a chart. It shows up in a fax queue. A claim gets denied, and somewhere in a hospital's business office, a trained professional begins a process that looks less like...
Join The Future Of Life Sciences Media
In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters — all in real time.
Don’t wait for the media to pick up your story. Be the media.
Trending
More News
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Closing the Interventional Gap
The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Transforming Clinical Outsourcing: From Reactive to Predictive Strategy
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Natural Diamonds in Healthcare
When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...
Clinical Trials Roundup | 03 April 2026
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
Erectile Dysfunction is Preventable – if You Act Early
Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...
Rethinking Lifestyle Diseases: From Risk Factors to Root Causes
Are we mistaking associations for true biological origins? Despite significant advances in modern medicine, lifestyle diseases such as cardiovascular disease and diabetes continue to rise globally. These conditions are commonly described as “multifactorial,”...
Rethinking Commercial Strategy for Late Biopharma Entrants
Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...
Clinical Trials Roundup | 10 April 2026
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The FDA PMTA Roundtable: Initial Reflections
Product characterisation remains the critical test of submission strength The US Food and Drug Administration (FDA) convened a roundtable on the Premarket Tobacco Product Application (PMTA) process, bringing together discussions on product characterisation,...
Beyond the Tumour: Can Radiotherapy Boost the Immune System?
Emerging research from a team of oncologists in Prague suggests that radiotherapy — long understood as a tool for destroying cancer cells — may also play a powerful role in activating the body's own immune defences. The implications for how we sequence and combine...
The Hidden ‘Perfect Healing’ Codes Within Your Body Have Been Deciphered
An axolotl loses its leg to a predator. Four weeks later, it has a functional replacement bones, nerves, muscles, and skin are perfectly re-formed. It is a biological masterpiece that has fascinated science for centuries. For decades, the prevailing dogma in...
Closing the Interventional Gap
The National Health Service (NHS) is investing heavily in diagnostics. Through Getting it Right First Time (GIRFT) and the rollout of Community Diagnostic Centres (CDCs), millions of patients are getting scans more quickly than ever[1]. The NHS 10 Year Plan has now...
Weekly News Roundup | 6 April 2026
Life science news 6 April 2026: A landmark obesity pill approval, 100% pharma tariffs and a record $6.3 billion life sciences fund headline a transformative week for the global pharmaceutical industry. The FDA approved Eli Lilly's once-daily obesity pill Foundayo...
Transforming Clinical Outsourcing: From Reactive to Predictive Strategy
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Natural Diamonds in Healthcare
When we say "diamonds," most people think of a luxurious necklace or a super sparkly ring. A research lab would be the last place people imagine them being used. Interestingly, natural diamonds are getting a lot of attention in science and healthcare research. And...
Clinical Trials Roundup | 03 April 2026
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
Erectile Dysfunction is Preventable – if You Act Early
Did you know that your erections can tell you more about your heart health than you might think? Nocturnal erections—those spontaneous erections that happen during sleep—are directly tied to vascular health. When a man stops having them, even for a short period of...
Rethinking Lifestyle Diseases: From Risk Factors to Root Causes
Are we mistaking associations for true biological origins? Despite significant advances in modern medicine, lifestyle diseases such as cardiovascular disease and diabetes continue to rise globally. These conditions are commonly described as “multifactorial,”...
Rethinking Commercial Strategy for Late Biopharma Entrants
Being first to market in a new therapeutic class is often seen as a winning formula in biopharma. In reality, many of the biggest commercial successes come second, or even later. The difference is not luck. It is timing, differentiation and scale. Understanding late...
Featured Articles
Further News
Python Blood Molecule Opens Door to New Obesity Treatments
Scientists studying the extraordinary metabolism of Burmese pythons have identified a python blood molecule that dramatically suppresses appetite in obese mice, raising the prospect of a new class of weight loss therapies that could avoid some of the side effects...
Weekly News Roundup | 30 March 2026
Life science news 30 March 2026: Three blockbuster deals, two FDA accelerated approvals and intensifying GLP-1 competition headline a busy week for pharma and biotech. Merck agreed on 25 March to acquire Terns Pharmaceuticals for $6.7 billion, gaining access to...
International Menopause Society Unveils Global Care Framework
International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
Clinical Trials Roundup | 27 March 2026
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
New Report Highlights Why CGTs Still Struggle at Market Access
Cell and gene therapies are approved — so why aren’t they reaching patients? New industry report warns access systems — not science — are now the primary bottleneck A new report from Phacilitate argues that the biggest threat to cell and gene therapy (CGT) expansion...
The Radical Longevity Science Frontier
For decades, longevity has been a frontier of scientific exploration, pushing the boundaries of what we believe is possible for human health and lifespan. While incremental progress has been made in understanding the biology of aging, we are now on the cusp of a new...
Key Thoughts from the on! PLUS TPL Review
The evolving PMTA landscape for nicotine pouches The recent FDA authorisation of on! PLUS nicotine pouches is a significant moment in helping meet tobacco harm reduction (THR) goals. They are the first products to pass a new, faster FDA programme, signifying a...
How to Move Faster Without Losing Scientific Rigor or Compliance
Life science organizations are under pressure to do two things at once: communicate complex science with precision and keep pace with a digital market that moves in days, not quarters. This tension defines one of the most consequential challenges in modern life...
Agentic AI is Having a Moment: The Foundations go Back 40 Years
The application of agentic AI in life sciences reached a tipping point in 2025. Frameworks where specialized agents collaborate on tasks, sharing work, dividing problems, communicating with each other, went from an emerging topic to the predominant conversation. For...
From Flower to Pharmacy: The Science Behind Manuka Honey
Not all honey is created equal. That statement, once dismissed as marketing language, is now well-supported by peer-reviewed chemistry. Manuka honey is produced by bees foraging on Leptospermum scoparium, a flowering shrub native to New Zealand and south-eastern...
Weekly News Roundup | 23 March 2026
Your essential life science news 23 March 2026 digest: the past week’s biggest stories in pharma, biotech and healthcare. The FDA approved Johnson and Johnson's once-daily psoriasis pill ICOTYDE (icotrokinra) on 18 March, making it the world's first oral peptide to...
Clinical Trials Roundup
This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...
Further News
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.
Don’t wait for the media to pick up your story. Be the media.
See More Articles
Want to Be Part of the Next Chapter in Life Sciences Media?
LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.